Hepatoprotective activity of Clearliv a polyherbal formulation in Wistar rats

Objective: To evaluate the hepatoprotective activity of Clearliv a polyherbal formulation in Wistar rats. Materials and Methods: The hepatoprotective potential of Clearliv was evaluated in thioacetamide-induced liver necrosis, DL-galactosamine [GalN]-induced liver injury, and carbon tetrachloride [CCl 4 ]-induced hepatitis models in Wistar rats. In all the models, Clearliv (at the dose levels of 800, and 1000 mg/kg) was administered for 3 days orally followed by single intraperitoneal administration of the hepatotoxicant on the last day after one hour of Clearliv administration. After 24 h of toxicant administration blood sample was collected by sino-orbital puncture in sodium EDTA tubes. The efficacy of Clearliv was evaluated by plasma biochemical parameters (AST, ALT, and ALP), and antioxidant enzyme (lipid peroxidation, catalase, superoxide dismutase, glutathione peroxidase, and hydroxyproline) levels. Results: In thioacetamide-induced necrosis, and GalN-induced liver injury models, Clearliv at 1000 mg/kg showed significant reduction in the elevated plasma liver markers, and elevated antioxidants levels. In CCl 4 -induced hepatitis, the Clearliv had favorable hepatoprotective effect, but the results were not significant. Conclusion: Clearliv 800, and 1000 mg/kg showed significant hepatoprotective effect against thioacetamide- and GalN-induced liver necrosis and injury, respectively